Results from the anaGO study – a phase 2 study with anakinra in patients with acute gout
Swedish Orphan Biovitrum AB (publ) (Sobi™) releases the primary efficacy results from the phase 2 study with anakinra in patients with acute gout – the anaGO study. For the primary endpoint of patient assessed pain intensity in the most affected joint there was a substantial reduction from baseline, both following treatment with anakinra and the comparator triamcinolone. There was a clinically meaningful pain reduction with anakinra of around 50% and in line with expectations of IL-1 blockade in this disease. No statistically significant difference between the two